Tidal Investments LLC Has $10.06 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Tidal Investments LLC lowered its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 50.8% during the second quarter, HoldingsChannel reports. The firm owned 19,109 shares of the company’s stock after selling 19,705 shares during the quarter. Tidal Investments LLC’s holdings in IDEXX Laboratories were worth $10,060,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth about $26,000. Virtus Advisers LLC acquired a new position in IDEXX Laboratories during the third quarter worth $26,000. J.Safra Asset Management Corp acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $25,000. Elevation Wealth Partners LLC boosted its stake in shares of IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after acquiring an additional 32 shares during the period. Finally, Wormser Freres Gestion increased its holdings in shares of IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.79% of the stock is owned by insiders.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent research reports. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. UBS Group upped their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Barclays decreased their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Stock Down 0.4%

Shares of IDEXX Laboratories stock opened at $504.70 on Friday. The firm has a market cap of $39.76 billion, a price-to-earnings ratio of 35.49, a PEG ratio of 2.70 and a beta of 1.54. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock’s 50-day moving average is $555.59 and its 200 day moving average is $566.45.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the business posted $3.50 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.